TOI Pengajuan SEC - The Oncology Institute, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1799191

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to The Oncology Institute, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 13, 2025	EX-10.2	At-The-Market Sales Agreement, dated August 13, 2025 between The Oncology Institute, Inc. and B. Riley Securities, Inc The Oncology Institute, Inc. UP TO $15,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENT August 13, 2025 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, New York 10022 Ladies and Gentlemen: The Oncology Institute, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities, Inc. (“B. Riley” and,
August 13, 2025	EX-99.1	The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., August 13, 2025 - The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025.
August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2025 THE ONCOLOGY INSTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commis
August 13, 2025	EX-10.3	Employment Agreement, dated May 12, 2025, between TOI Management, LLC and Jeff Langsam EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of May 12, 2025 (the “Effective Date”), by and between TOI Management, LLC, a Delaware limited liability company (the “Company”), and Jeff Langsam, D.
August 13, 2025	EX-10.1	At-The-Market Sales Agreement, dated August 13, 2025 between The Oncology Institute, Inc. and BTIG, LLC The Oncology Institute, Inc. UP TO $15,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENT August 13, 2025 BTIG, LLC 65 East 55th Street New York, New York 10022 Ladies and Gentlemen: The Oncology Institute, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), a
August 13, 2025	424B5	The Oncology Institute, Inc. Common Stock Filed pursuant to Rule 424(b)(5) Registration No.: 333-287848 AMENDMENT NO. 1 (To prospectus supplement dated June 18, 2025 and accompanying prospectus dated June 18, 2025) The Oncology Institute, Inc. $15,000,000 Common Stock This prospectus amendment no. 1, or this amendment, amends the prospectus dated June 18, 2025, or the original prospectus supplement. This amendment should be read in conjun
August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2025 THE ONCOLOGY INSTIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commiss
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolog
August 13, 2025	EX-99.1	The Oncology Institute Announces Changes to Board of Directors Exhibit 99.1 The Oncology Institute Announces Changes to Board of Directors Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman CERRITOS, Calif., August 13, 2025 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that Richard Barasch will retire
June 16, 2025	EX-1.2	Form of Sales Agreement between The Oncology Institute, Inc. and BTIG, LLC. Exhibit 1.2 The Oncology Institute, Inc. UP TO $15,000,000 OF COMMON STOCK (par value $0.0001 per share) At-the-market SALES AGREEMENT [●], 2025 BTIG, LLC 65 East 55th Street New York, New York 10022 Ladies and Gentlemen: The Oncology Institute, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Partie
June 16, 2025	S-3/A	As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No.
June 16, 2025	CORRESP	THE ONCOLOGY INSTITUTE, INC. 18000 Studebaker Road, Suite 800 Cerritos, CA 90703 Correspondence THE ONCOLOGY INSTITUTE, INC. 18000 Studebaker Road, Suite 800 Cerritos, CA 90703 June 16, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Robert Augustin Re: The Oncology Institute, Inc. Registration Statement on Form S-3, filed June 6, 2025 File No. 333-2
June 6, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) The Oncology Institute, Inc.
June 6, 2025	S-3	As filed with the Securities and Exchange Commission on June 6, 2025 As filed with the Securities and Exchange Commission on June 6, 2025 Registration No.
May 19, 2025	EX-99.1	1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION May 2025 Exhibit 99.1 1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION May 2025 This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the PIPE Financing) involving The Oncology Institute, Inc. (the ”Company“), and for no other purpose. This presentation is for informational purposes only and is being provided to you solely in your capacity as a
May 19, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commissio
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolo
May 14, 2025	EX-99.1	The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 - The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Re
May 14, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commissio
May 14, 2025	CORRESP	THE ONCOLOGY INSTITUTE, INC. 18000 Studebaker Road, Suite 800 Cerritos, CA 90703 Correspondence THE ONCOLOGY INSTITUTE, INC. 18000 Studebaker Road, Suite 800 Cerritos, CA 90703 May 14, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Juan Grana Re: The Oncology Institute, Inc. Registration Statement on Form S-3, filed May 8, 2025 File No. 333-287138 D
May 8, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) The Oncology Institute, Inc.
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2025 THE ONCOLOGY INSTITUTE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commission
May 8, 2025	S-3	As filed with the Securities and Exchange Commission on May 8, 2025 As filed with the Securities and Exchange Commission on May 8, 2025 Registration No.
May 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 THE ONCOLOGY INSTITUTE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commission
April 11, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commissi
March 27, 2025	EX-10.1	Registration Rights Agreement, dated March 26, 2025, by and among the Company and the Investors signatory thereto. Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2025, is entered into by and among The Oncology Institute, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized term
March 27, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
March 27, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commiss
March 27, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 26, 2025	EX-10.19	Insider Trading Compliance Policy The Oncology Institute, Inc. Insider Trading Compliance Policy Federal and state laws prohibit trading in the securities of a company while in possession of material non-public information and providing material non-public information to others so that they can trade. Violating such laws can undermine investor trust, harm The Oncology Institute, Inc.’s reputation, and result in your dismissal from
March 26, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncology In
March 26, 2025	EX-97.1	The Oncology Institute, Inc. Policy for Recovery of Erroneously Awarded Compensation THE ONCOLOGY INSTITUTE, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Oncology Institute, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 17, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Polic
March 25, 2025	EX-10.1	Securities Purchase Agreement, dated March 24, 2025, by and among the Company and the Purchasers. Exhibit 10.1 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE OMITTED PORTIONS OF THIS DOCUMENT ARE INDICATED BY [***]. SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 24, 2025, by and among The Oncology Institute, Inc., a Delaware co
March 25, 2025	EX-10.2	Exchange Agreement, dated March 24, 2025, by and among the Company and the Deerfield Parties Exhibit 10.2 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (including the schedules, annexes and exhibits hereto, this “Agreement”), dated as of March 24, 2025, is entered into by and among The Oncology Institute, Inc., a Delaware corporation (the “Company”), Deerfield Private Design Fund V, L.P., (“DPD V”) Deerfield Private Design Fund IV, L.P. (“DPD IV”), and Deerfield Partners, L.P. (“DP” and toge
March 25, 2025	EX-99.1	The Oncology Institute Announces $16.5 million Private Placement Exhibit 99.1 The Oncology Institute Announces $16.5 million Private Placement CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited
March 25, 2025	EX-4.2	Form of Common Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 25, 2025	EX-10.3	Form of Registration Rights Agreement. Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March [], 2025, is entered into by and among The Oncology Institute, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized term
March 25, 2025	EX-3.1	Certificate of Correction to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock. Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CORRECTION TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK OF THE ONCOLOGY INSTITUTE, INC. The Oncology Institute, Inc. (formerly known as DFP Healthcare Acquisitions Corp.), a corporation organized and existing under and by virtue of the General Corporation Law of the
March 25, 2025	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commiss
March 25, 2025	EX-4.1	Form of pre-funded Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 25, 2025	EX-4.3	Form of Deerfield Common Warrant Exhibit 4.3 COMMON STOCK PURCHASE WARRANT the ONCOLOGY INSTITUTE, inc. Warrant Shares: [•] Initial Exercise Date: [•] Issue Date: March [•], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af
March 25, 2025	EX-3.2	Certificate of Amendment to Certificate of Designation of Series A Common Stock Equivalent Convertible Preferred Stock. Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK OF THE ONCOLOGY INSTITUTE, INC. The Oncology Institute, Inc. (the “Company”), organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: The Board of Directo
March 24, 2025	EX-99.1	The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025 Exhibit 99.1 FOR IMMEDIATE RELEASE The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025 CERRITOS, Calif., March 24, 2025 - The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended Decemb
March 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2025 THE ONCOLOGY INSTIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commiss
March 24, 2025	EX-99.1	1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION QŦǐğƠƬűƘͭ ƘğƠğŦƬôƬńűŦ February 2025 Exhibit 99.1 1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION QŦǐğƠƬűƘͭ ƘğƠğŦƬôƬńűŦ February 2025 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION %ńƠđśôńŤğƘ This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the “ PIP E Financing”) involving The Oncology Institute, Inc. (the “Company”), and for no other purpose. This presentation is f
March 24, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commiss
March 14, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
February 26, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 26, 2025 THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Comm
February 26, 2025	EX-99.1	The Oncology Institute Announces Amendment to Facility Agreement and Debt Paydown Exhibit 99.1 The Oncology Institute Announces Amendment to Facility Agreement and Debt Paydown CERRITOS, Calif., February 26, 2025 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced an amendment to its existing facility agreement with funds affiliated with Deerfield M
February 26, 2025	EX-10.1	Limited Consent and Amendment No. 1 to Facility Agreement, dated as of February 26, 2025, by and among The Oncology Institute, Inc., the other loan parties party thereto, the lenders party thereto and Deerfield Partners, L.P. Exhibit 10.1 LIMITED CONSENT AND AMENDMENT NO. 1 TO FACILITY AGREEMENT This Limited Consent and Amendment No. 1 to Facility Agreement (this “Agreement”), dated as of February 26, 2025 (the “Effective Date”), is entered into by and among The Oncology Institute, Inc., a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders, and Deerfield Partners, L.P., as agent for
December 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) THE ONCOLOGY INS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Comm
November 13, 2024	EX-10.1	Employment agreement, effective as of September 30, 2024, by and between the Company and Robert Carter Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2024 (the “Effective Date”), by and between TOI Management, LLC, a Delaware limited liability company (the “Company”), and Rob Carter (the “Executive”). The Company and the Executive may be referred to together as the “Parties” and individually as a “Party.” Capitalized terms
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The On
November 13, 2024	EX-99.1	The Oncology Institute Reports Third Quarter 2024 Financial Results FOR IMMEDIATE RELEASE The Oncology Institute Reports Third Quarter 2024 Financial Results CERRITOS, Calif.
November 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2024 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
November 12, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 11, 2024 (November 8, 2024) Date of Report (Date of earliest event reported) THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of i
September 23, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 19, 2024 Date of Report (Date of earliest event reported) THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Com
September 23, 2024	EX-99.1	The Oncology Institute Announces CFO Transition EXHIBIT 99.1 The Oncology Institute Announces CFO Transition Rob Carter promoted to Chief Financial Officer CERRITOS, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), today announced that Chief Financial Officer, Mihir Shah, will transition out of the organization effective October 14, 2024, to pursue other opportunities. Rob Carter, Se
August 20, 2024	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / Havencrest Healthcare Partners, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 23343Q100 (CUSIP Number) Christopher Kersey Manager 2100 McKinney Ave, Suite 1760 Dallas, Texas 75201 Tel: (214) 420-3481 (Name, Address
August 13, 2024	EX-99.1	The Oncology Institute Reports Second Quarter 2024 Financial Results and Updates Full Year 2024 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports Second Quarter 2024 Financial Results and Updates Full Year 2024 Guidance CERRITOS, Calif.
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolog
August 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2024 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
June 21, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 21, 2024 (June 20, 2024) Date of Report (Date of earliest event reported) THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorpor
June 13, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 13, 2024 Date of Report (Date of earliest event reported) THE ONCOLOGY INSTITUTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39248 84-3562323 (State or other jurisdiction of incorporation) (Commissi
May 22, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3
May 22, 2024	CORRESP	The Oncology Institute, Inc. 18000 Studebaker Rd., Suite 800, Cerritos, California 90703 May 22, 2024 The Oncology Institute, Inc. 18000 Studebaker Rd., Suite 800, Cerritos, California 90703 May 22, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission Attention: Tracey Houser, Terence O’Brien Re: The Oncology Institute, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Filed March 28, 2024 File No. 001-3
May 22, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolo
May 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2024 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Comm
May 14, 2024	EX-99.1	The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance CERRITOS, Calif.
May 2, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
May 2, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De
April 22, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3
April 22, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 3, 2024	EX-99.1	1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation April 2024 2THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Disclaimer FORWARD LOOKING STATEMENTS This presentation includes certain statements that are not historical facts but are forwa 1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation April 2024 2THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Disclaimer FORWARD LOOKING STATEMENTS This presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.
April 3, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 3, 2024 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Com
March 28, 2024	EX-4.5	Description of Registered Securities of The Oncology Institute, Inc. EXHIBIT 4.5 DESCRIPTION OF CAPITAL STOCK The following is a description of the capital stock of The Oncology Institute, Inc. (“TOI” the “Company,” “we,” “us,” and “our”) and certain provisions of our amended and restated certificate of incorporation (the “certificate of incorporation”), our amended and restated bylaws (the “bylaws”) and the General Corporation Law of the State of Delaware (the “DG
March 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncology In
March 28, 2024	EX-97.1	The Oncology Institute, Inc. Policy for Recovery of Erroneously Awarded Compensation THE ONCOLOGY INSTITUTE, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Oncology Institute, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 17, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Polic
March 27, 2024	EX-99.1	The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024 FOR IMMEDIATE RELEASE The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024 CERRITOS, Calif.
March 27, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2024 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
January 2, 2024	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / Havencrest Healthcare Partners, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d32418dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 23343Q100 (CUSIP Number) Christopher Kersey Manager 2100 McKinney Ave, Suite 1760 Dallas, Texas 75201 Tel: (
November 8, 2023	EX-99.1	The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance CERRITOS, Calif.
November 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (
November 8, 2023	EX-10.2	Employment Agreement, effective as of September 5, 2023, by and between the Company and Jeremy Castle EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of September 5, 2023 (the “Effective Date”), by and between TOI Management, LLC, a Delaware limited liability company (the “Company”), and Jeremy Castle (the “Executive”).
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The On
September 18, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 15, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
September 18, 2023	EX-99.1	The Oncology Institute Regains Compliance with Nasdaq Listing Requirements The Oncology Institute Regains Compliance with Nasdaq Listing Requirements CERRITOS, California, Sept.
September 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 6, 2023 Date of Report (date of earliest event reported) The Oncology Ins UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 6, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
September 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2023 Date of Report (date of earliest event reported) The Oncology Ins UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
August 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 30, 2023 Date of Report (date of earliest event reported) The Oncology Insti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 30, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
August 10, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
August 10, 2023	EX-99.1	1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation AUGUST 2023 2THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Disclaimer FORWARD LOOKING STATEMENTS This press release includes certain statements that are not historical facts but are for 1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation AUGUST 2023 2THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Disclaimer FORWARD LOOKING STATEMENTS This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.
August 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
August 9, 2023	EX-99.1	The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance CERRITOS, Calif.
August 9, 2023	EX-32.,2	Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer EXHIBIT 32.2 Certification of Chief Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) In connection with the Quarterly Report of The Oncology Institute, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mihir Shah, Chief Fin
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolog
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 15, 2023 The Oncology Instit UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 15, 2023 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
June 15, 2023	EX-10.1	Limited Consent, dated as of June 14, 2023, by and among the Company and Deerfield EX-10.1 2 tm2318791d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 LIMITED CONSENT This Limited Consent, dated as of June 14, 2023 (this “Consent”), is granted in connection with the Facility Agreement, dated as of August 9, 2022 (as amended or otherwise modified from time to time, the “Agreement”), by and among The Oncology Institute, Inc., a Delaware corporation (the “Borrower”), the other Loan Parties p
June 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 14, 2023 The Oncology Instit UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 14, 2023 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
June 14, 2023	EX-10.3	Employment Agreement, dated February 18, 2020, between the TOI Management, LLC and Daniel Virnich. Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of February 18, 2020 (the “Effective Date”), by and between TOI Management, LLC, a Delaware limited liability company (the “Company”), and Daniel Virnich, M.D. (the “Executive”). The Company and the Executive may be referred to together as the “Parties” and individually as a “Party.” Capitali
June 14, 2023	EX-10.1	June 11, 2023, by and among The Oncology Institute, Inc., TOI Management, Exhibit 10.1 TRANSITION AGREEMENT This TRANSITION AGREEMENT (the “Agreement”) is entered into by and among the undersigned (“Executive”), TOI Management, LLC, a Delaware limited liability company (“Management”), and The Oncology Institute, Inc., a Delaware corporation (“Parent” and, together with Management and their direct and indirect subsidiaries, the “Company”), effective as of June 11, 2023 (
June 14, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
June 14, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2023 The Oncology Insti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2023 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
June 14, 2023	EX-99.1	THE ONCOLOGY INSTITUTE ANNOUNCES LEADERSHIP TRANSITION THE ONCOLOGY INSTITUTE ANNOUNCES LEADERSHIP TRANSITION Dr. Daniel Virnich promoted from President to CEO. Brad Hively will transition from CEO to Vice Chairman. Cerritos, CA. – June 12, 2023 – The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of
June 14, 2023	EX-10.2	Amended and Restated Employment Agreement, dated as of December 16, 2019, between the TOI Management, LLC and Brad Hively Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of December 16, 2019, by and between TOI Management, LLC, a Delaware limited liability company (the "Company"), and Bradford Hively (the "Executive"). The Company and the Executive may be referred to together as the "Parties" and individually as a "Pa
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2023 Date of Report (date of earliest event reported) The Oncology Institu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Com
June 12, 2023	EX-99.1	6/9/23, 1:42 PM the-oncology-institute-announces-leadership-transition https://prdesk.globenewswire.com/JobPreview/PnrArticlePreview?t=5640719&l=eng 1/2 The Oncology Institute Announces Leadership Transition Dr. Daniel Virnich promoted from President ex991-toitransitionpress 6/9/23, 1:42 PM the-oncology-institute-announces-leadership-transition https://prdesk.
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2023 Date of Report (date of earliest event reported) The Oncology Institut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Comm
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2023 Date of Report (date of earliest event reported) The Oncology Institut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Comm
May 10, 2023	EX-10.2	Amendment No. 1 to Employment Agreement dated April 4, 2023 between TOI Management LLC and Mihir Shah dated May 4, 2023 shah-firstamendmenttoemp US-DOCS\140649349.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to the Employment Agreement (the “Agreement”) previously entered into between TOI Management, LLC, a Delaware limited liability company (the “Company”), on the one hand, and Mihir Shah (the “Executive”), on the other hand, dated effective as of April 4, 2022, is made effective on May 4, 2023 (
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolo
May 10, 2023	EX-10.1	Amendment No. 1 to Employment Agreement dated February 18, 2020 between TOI Management LLC and Daniel Virnich dated May 4, 2023 virnich-firstamendmentto US-DOCS\140649264.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to the Employment Agreement (the “Agreement”) previously entered into between TOI Management, LLC, a Delaware limited liability company (the “Company”), on the one hand, and Daniel Virnich, M.D. (the “Executive”), on the other hand, dated effective as of February 18, 2020, is made effective on
May 10, 2023	EX-99.1	The Oncology Institute Reports First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance CERRITOS, Calif.
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2023 Date of Report (date of earliest event reported) The Oncology Instit UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
April 3, 2023	SC 13G/A	DFPH / DFP Healthcare Acquisitions Corp / Agajanian Richy - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oncology Institute, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 23343Q100 (CUSIP Number) March 31, 2023 (Date of Event Which Requires Filling of This Statement) Check the appropriate box to designate the r
March 27, 2023	EX-99.1	Investor Presentation March 2023 Disclaimer Forward Looking Statements Financial Information; Non-GAAP Financial Measures This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of toiinvestorpresentation2 Investor Presentation March 2023 Disclaimer Forward Looking Statements Financial Information; Non-GAAP Financial Measures This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.
March 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2023 Date of Report (date of earliest event reported) The Oncology Instit UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
March 17, 2023	EX-99.1	The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023 EX-99.1 2 item991-q42022earningsrele.htm EX-99.1 FOR IMMEDIATE RELEASE CORRECTION - The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023 The Company recorded adjustments to its “goodwill impairment charges” and “income tax benefit” line items on the “Consolidated Statements of Operations” for the fourth quarter and year ended December 31,
March 17, 2023	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
March 16, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncology In
March 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2023 Date of Report (date of earliest event reported) The Oncology Institu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2023 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Com
March 9, 2023	EX-99.1	The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023 FOR IMMEDIATE RELEASE The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023 CERRITOS, Calif.
February 10, 2023	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 87,829,226 Shares of Common Stock Up to 3,177,542 Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-261740 Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 87,829,226 Shares of Common Stock Up to 3,177,542 Warrants This prospectus relates to the issuance by us of up to an aggregate of up to 8,927,528 shares of our common stock, $0.0001 par value per share (“Common Stock”), which consists of (i) up to 3,177,542 s
February 10, 2023	424B3	Up to 1,227,161 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-265065 Up to 1,227,161 Shares of Common Stock This prospectus relates to the offer and sale from time to time by certain of the securityholders (including their transferees, donees, pledgees and other successors-in-interest) named in this prospectus (the “Registered Holders”) of up to an aggregate of 1,227,161 shares of our common stock, $0.0
January 30, 2023	POS AM	As filed with the Securities and Exchange Commission on January 27, 2023 As filed with the Securities and Exchange Commission on January 27, 2023 Registration No.
January 30, 2023	POS AM	As filed with the Securities and Exchange Commission on January 27, 2023 As filed with the Securities and Exchange Commission on January 27, 2023 Registration No.
January 10, 2023	SC 13G/A	DFPH / DFP Healthcare Acquisitions Corp / Agajanian Richy - SCHEDULE 13G/A Passive Investment SC 13G/A 1 raga20230109sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncology Institute, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 23343Q100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filling of This Sta
January 9, 2023	424B3	Up to 20,459,040 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-267324 Up to 20,459,040 Shares of Common Stock This prospectus relates to the offer and sale from time to time by certain of the securityholders (including their transferees, donees, pledgees and other successors-in-interest) named in this prospectus (each, a “Registered Holder” and, collectively, the “Registered Holders”) of an aggregate of u
December 30, 2022	POS AM	As filed with the Securities and Exchange Commission on December 30, 2022 As filed with the Securities and Exchange Commission on December 30, 2022 Registration No.
December 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 27, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
December 1, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 8 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
December 1, 2022	424B3	Up to 1,342,076 Shares of Common Stock ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-265065 PROSPECTUS SUPPLEMENT NO. 6 (to prospectus dated June 3, 2022) Up to 1,342,076 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 3, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityholders (inclu
December 1, 2022	424B3	Up to 20,459,040 Shares of Common Stock Filed pursuant to Rule 424(b)(3) ?Registration No. 333-267324 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated September 26, 2022) Up to 20,459,040 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated September 26, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityho
November 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2022 Date of Report (date of earliest event reported) The Oncology Ins UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
November 15, 2022	EX-99.1	Investor Presentation November 2022 Disclaimer Forward Looking Statements Financial Information; Non-GAAP Financial Measures This presentation includes certain statements that are not historical facts but are forward-looking statements for purposes o toiinvestorpresentation Investor Presentation November 2022 Disclaimer Forward Looking Statements Financial Information; Non-GAAP Financial Measures This presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.
November 10, 2022	424B3	Up to 20,459,040 Shares of Common Stock Filed pursuant to Rule 424(b)(3) ?Registration No. 333-267324 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated September 26, 2022) Up to 20,459,040 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated September 26, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityho
November 10, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 7 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
November 10, 2022	424B3	Up to 1,342,076 Shares of Common Stock ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-265065 PROSPECTUS SUPPLEMENT NO. 5 (to prospectus dated June 3, 2022) Up to 1,342,076 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 3, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityholders (inclu
November 9, 2022	EX-99.1	The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance CERRITOS, Calif.
November 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The On
November 7, 2022	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / Havencrest Healthcare Partners, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 23343Q100 (CUSIP Number) Christopher Kersey Manager 2100 McKinney Ave, Suite 1760 Dallas, Texas 75201 Tel: (214) 420-3481 (Name, Address
September 26, 2022	424B3	Up to 20,459,040 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-267324 Up to 20,459,040 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders (including their transferees, donees, pledgees and other successors-in-interest) named in this prospectus (the ?Selling Securityholders?) of an aggregate of up to 20,459,040 shares of our common stock, pa
September 26, 2022	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / M33 Growth I L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 23343Q100 (CUSIP Number) Gabriel Ling c/o M33 Growth I LP 888 Boylston Street, Suite 500 Boston, MA 02199 (Name, Address and Telephone N
September 23, 2022	S-1/A	As filed with the U.S. Securities and Exchange Commission on September 23, 2022 As filed with the U.S. Securities and Exchange Commission on September 23, 2022 Registration No. 333-267324 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 84-356323 (State or other jurisdiction
September 22, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248
September 22, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 6 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
September 22, 2022	424B3	Up to 1,342,076 Shares of Common Stock ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-265065 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated June 3, 2022) Up to 1,342,076 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 3, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityholders (inclu
September 22, 2022	EX-99.1	The Oncology Institute Appoints Two New Board Members The Oncology Institute Appoints Two New Board Members Expands board to 9 members with deep healthcare management and investment experience CERRITOS, Calif.
September 21, 2022	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / Havencrest Healthcare Partners, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 23343Q100 (CUSIP Number) Christopher Kersey Manager 2100 McKinney Ave, Suite 1760 Dallas, Texas 75201 Tel: (214) 420-3481 (Name, Address and Telep
September 8, 2022	S-1	As filed with the U.S. Securities and Exchange Commission on September 7, 2022 As filed with the U.S. Securities and Exchange Commission on September 7, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 84-356323 (State or other jurisdiction of incorporation or organ
September 8, 2022	EX-FILING FEES	Calculation of Filing Fees Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) The Oncology Institute, Inc.
August 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 16, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
August 16, 2022	EX-99.1	Investor Presentation August 2022 Disclaimer Forward Looking Statements This presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Investor Presentation August 2022 Disclaimer Forward Looking Statements This presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.
August 10, 2022	EX-10.2	Registration Rights Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners LP REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of August 9, 2022, by and among (i) The Oncology Institute, Inc.
August 10, 2022	EX-4.1	Form of Secured Convertible Note Final Form THE OFFER AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS.
August 10, 2022	EX-4.2	Form of Warrant THE OFFER AND SALE OF THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAW.
August 10, 2022	EX-4.1	Form of Secured Convertible Note Final Form THE OFFER AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS.
August 10, 2022	EX-10.1	Facility Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners LP EXECUTION VERSION US153737865v8 FACILITY AGREEMENT dated as of August 9, 2022 by and among The Oncology Institute, Inc.
August 10, 2022	424B3	Up to 1,342,076 Shares of Common Stock ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-265065 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated June 3, 2022) Up to 1,342,076 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 3, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityholders (inclu
August 10, 2022	EX-99.1	The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets Investment to accelerate Company’s expansion into new markets, bringing high-quality, value-based care to more pat The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets Investment to accelerate Company?s expansion into new markets, bringing high-quality, value-based care to more patients CERRITOS, Calif.
August 10, 2022	EX-4.2	Form of Warrant THE OFFER AND SALE OF THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAW.
August 10, 2022	EX-10.3	Registration Rights Consent, Amendment, and Waiver, dated as of August 9, 2022, by and among Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P., M33 Growth I L.P., TOI M, LLC and Oncology Care Partners, LLC THE ONCOLOGY INSTITUTE, INC. REGISTRATION RIGHTS CONSENT, AMENDMENT, AND WAIVER Reference is made to that certain Amended and Restated Registration Rights Agreement, dated as of November 12, 2021, by and among The Oncology Institute, Inc. (f/k/a DFP Healthcare Acquisitions Corp.), a Delaware corporation (the ?Company?), DFP Sponsor LLC, a Delaware limited liability company (the ?Sponsor?), and eac
August 10, 2022	EX-10.3	Registration Rights Consent, Amendment, and Waiver, dated as of August 9, 2022, by and among Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P., M33 Growth I L.P., TOI M, LLC, and Oncology Care Partners, LLC. THE ONCOLOGY INSTITUTE, INC. REGISTRATION RIGHTS CONSENT, AMENDMENT, AND WAIVER Reference is made to that certain Amended and Restated Registration Rights Agreement, dated as of November 12, 2021, by and among The Oncology Institute, Inc. (f/k/a DFP Healthcare Acquisitions Corp.), a Delaware corporation (the ?Company?), DFP Sponsor LLC, a Delaware limited liability company (the ?Sponsor?), and eac
August 10, 2022	EX-10.1	Facility Agreement, dated as of August 9, 2022, by and among the Company and Deerfield Partners L.P. EXECUTION VERSION US153737865v8 FACILITY AGREEMENT dated as of August 9, 2022 by and among The Oncology Institute, Inc.
August 10, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2022 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
August 10, 2022	424B3	Up to 1,342,076 Shares of Common Stock ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-265065 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated June 3, 2022) Up to 1,342,076 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 3, 2022 (the ?Prospectus?), related to the offer and sale from time to time by the selling securityholders (inclu
August 10, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
August 10, 2022	EX-10.3	Registration Rights Consent, Amendment, and Waiver, dated as of August 9, 2022, by and among Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P., M33 Growth I L.P., TOI M, LLC, and Oncology Care Partners, LLC. THE ONCOLOGY INSTITUTE, INC. REGISTRATION RIGHTS CONSENT, AMENDMENT, AND WAIVER Reference is made to that certain Amended and Restated Registration Rights Agreement, dated as of November 12, 2021, by and among The Oncology Institute, Inc. (f/k/a DFP Healthcare Acquisitions Corp.), a Delaware corporation (the ?Company?), DFP Sponsor LLC, a Delaware limited liability company (the ?Sponsor?), and eac
August 10, 2022	EX-10.2	Registration Rights Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners LP REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of August 9, 2022, by and among (i) The Oncology Institute, Inc.
August 10, 2022	EX-10.2	Registration Rights Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners L.P. REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of August 9, 2022, by and among (i) The Oncology Institute, Inc.
August 10, 2022	EX-10.2	Registration Rights Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners LP REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of August 9, 2022, by and among (i) The Oncology Institute, Inc.
August 10, 2022	424B3	Up to 1,342,076 Shares of Common Stock ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-265065 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated June 3, 2022) Up to 1,342,076 Shares of Common Stock This prospectus supplement no. 3 amends and restates in its entirety the prospectus supplement no. 2, dated August 9, 2022, filed with the Securities and Exchange Commission (?SEC?) pursuant to Rule 424(b) solely for the purpose of eli
August 10, 2022	EX-4.2	Form of Warrant THE OFFER AND SALE OF THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAW.
August 10, 2022	EX-4.1	Form of Secured Convertible Note Final Form THE OFFER AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS.
August 10, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 5 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
August 10, 2022	EX-4.2	Form of Warrant THE OFFER AND SALE OF THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAW.
August 10, 2022	EX-10.3	Registration Rights Consent, Amendment, and Waiver, dated as of August 9, 2022, by and among Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P., M33 Growth I L.P., TOI M, LLC, and Oncology Care Partners, LLC THE ONCOLOGY INSTITUTE, INC. REGISTRATION RIGHTS CONSENT, AMENDMENT, AND WAIVER Reference is made to that certain Amended and Restated Registration Rights Agreement, dated as of November 12, 2021, by and among The Oncology Institute, Inc. (f/k/a DFP Healthcare Acquisitions Corp.), a Delaware corporation (the ?Company?), DFP Sponsor LLC, a Delaware limited liability company (the ?Sponsor?), and eac
August 10, 2022	EX-10.1	Facility Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners LP EX-10.1 4 a101facilityagreementexe.htm EX-10.1 EXECUTION VERSION US153737865v8 FACILITY AGREEMENT dated as of August 9, 2022 by and among The Oncology Institute, Inc., as the Borrower, the other Loan Parties party hereto from time to time, the Lenders and DEERFIELD PARTNERS, L.P., as agent for itself and the Secured Parties i US153737865v8 Table of Contents ARTICLE 1 DEFINITIONS ..................
August 10, 2022	EX-10.1	Facility Agreement, dated as of August 9, 2022, by and among The Oncology Institute, Inc. and Deerfield Partners LP EXECUTION VERSION US153737865v8 FACILITY AGREEMENT dated as of August 9, 2022 by and among The Oncology Institute, Inc.
August 10, 2022	EX-4.1	Form of Secured Convertible Note Final Form THE OFFER AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS.
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolog
August 9, 2022	EX-99.1	The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance CERRITOS, Calif.
August 9, 2022	EX-10.1	Separation Agreement by and between the Company and Scott Dalgleish SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (the ?Agreement?) is entered into by and among Scott Dalgleish (?Executive?), The Oncology Institute, Inc.
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
July 15, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2022 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
July 12, 2022	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / M33 Growth I L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 23343Q100 (CUSIP Number) Gabriel Ling c/o M33 Growth I LP 888 Boylston Street, Suite 500 Boston, MA 02199 (Name, Address and Telephone N
July 11, 2022	SC 13D/A	DFPH / DFP Healthcare Acquisitions Corp / Havencrest Healthcare Partners, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 23343Q100 (CUSIP Number) Christopher Kersey Manager 2100 McKinney Ave, Suite 1760 Dallas, Texas 75201 Tel: (214) 420-3481 (Name, Add
June 3, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
June 3, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
June 3, 2022	424B3	Up to 1,342,076 Shares of Common Stock? 424B3 1 tm2213606-3424b3.htm 424B3 TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-265065 Up to 1,342,076 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders (including their transferees, donees, pledgees and other successors-in-interest) named in this prospectus (the “Selling Securityholders”) of up to an
May 19, 2022	S-1	As filed with the U.S. Securities and Exchange Commission on May 19, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on May 19, 2022 Registration No. 333- ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) ? Delaware 8011 84-356323 (State or other jurisdiction of (
May 19, 2022	EX-10.9	Form of Physician RSU Agreement Exhibit 10.9 ? AMENDED AND RESTATED RESTRICTED STOCK AGREEMENT WITH RESPECT TO SERIES A PREFERRED STOCK OF TOI PARENT, INC., A DELAWARE CORPORATION ? ? ? Name of Grantee: (the ?Grantee?) Number of shares of Series A Preferred Stock: shares of Series A Preferred Stock (the ?Restricted Stock?) ? ? ? RECITALS WHEREAS, the Grantee and Jimmy Holdings entered into certain Restricted Stock Agreement(s) w
May 19, 2022	EX-FILING FEES	EX-Filing Fees Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) The Oncology Institute, Inc.
May 12, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) The Oncology Institute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities EX-FILING FEES 2 exhibit107-filingfeesxs820.htm EX-FILING FEES EX-107 Calculation of Filing Fee Tables S-8 (Form Type) The Oncology Institute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate
May 12, 2022	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on May 12, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware 84-356323 (State or other jurisdiction of incorporation or organization) (
May 12, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2022 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Com
May 12, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
May 11, 2022	EX-99.1	The Oncology Institute Reports First Quarter 2022 Financial Results and Confirms Full Year 2022 Guidance FOR IMMEDIATE RELEASE The Oncology Institute Reports First Quarter 2022 Financial Results and Confirms Full Year 2022 Guidance CERRITOS, Calif.
May 11, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Comm
May 10, 2022	EX-10.1	Executive Employment Agreement- Mihir Shah EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of April 4, 2022 (the ?Effective Date?), by and between TOI Management, LLC, a Delaware limited liability company (the ?Company?), and Mihir Shah (the ?Executive?).
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncolo
May 9, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated May 3, 2022) Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 3, 2022 (the ?P
May 6, 2022	424B3	Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(3)? ??Registration No. 333-261740? Up to 8,927,528 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 90,477,403 Shares of Common Stock Up to 3,177,542 Warrants? ? This prospectus relates to the issuance by us of up to an aggregate of up to 8,927,528 shares of our common stock, $0.0001 par value per share (?Common Stock?), which consist
May 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2022 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (C
April 29, 2022	POS AM	As filed with the U.S. Securities and Exchange Commission on April 29, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on April 29, 2022 Registration No. 333-261740 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) ? Delaware 8011 8
April 4, 2022	EX-99.1	The Oncology Institute Names Mihir Shah as Chief Financial Officer Shah Brings 15 Years of Financial Leadership in Public and Private Healthcare Companies The Oncology Institute Names Mihir Shah as Chief Financial Officer Shah Brings 15 Years of Financial Leadership in Public and Private Healthcare Companies CERRITOS, Calif.
April 4, 2022	424B3	Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated February 11, 2022) Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 11,
April 4, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 1, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Com
March 18, 2022	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organiza
March 18, 2022	EX-99.1	Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Relationships with Leading Payors and Risk Tak Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Relationships with Leading Payors and Risk Taking Providers Our Growth (Revenue, $ millions) $66 $203 2016A 2021A 25.
March 11, 2022	EX-99.1	Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Relationships with Leading Payors and Risk Tak Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Relationships with Leading Payors and Risk Taking Providers Our Growth (Revenue, $ millions) $66 $203 2016A 2021A 25.
March 11, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39248 The Oncology In
March 11, 2022	424B3	Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated February 11, 2022) Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 11,
March 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
March 10, 2022	EX-99.1	The Oncology Institute Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Strong Growth Outlook for 2022 EX-99.1 2 item991-2021earningsand202.htm EX-99.1 FOR IMMEDIATE RELEASE The Oncology Institute Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Strong Growth Outlook for 2022 CERRITOS, Calif. – March 10, 2022 The Oncology Institute (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth qua
March 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Co
March 8, 2022	424B3	Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants ?Filed pursuant to Rule 424(b)(3) ?Registration No. 333-261740 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated February 14, 2022) Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 14,
March 8, 2022	EX-10.1	Form of Restricted Stock Unit Agreement Exhibit 10.1 THE ONCOLOGY INSTITUTE, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE The Oncology Institute, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of The Oncology
March 8, 2022	EX-10.2	Form of Option Agreement EX-10.2 3 exhibit102-formofoptionagr.htm EX-10.2 Exhibit 10.2 THE ONCOLOGY INSTITUTE, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE The Oncology Institute, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”), subject to the terms and condi
March 7, 2022	EX-99.1	The Oncology Institute Announces Promotions for Dr. Daniel Virnich and Dr. Matt Miller EX-99.1 4 exhitbit991-leadershipupda.htm EX-99.1 FOR IMMEDIATE RELEASE The Oncology Institute Announces Promotions for Dr. Daniel Virnich and Dr. Matt Miller Leaders Will Take on Expanded Roles in Response to TOI’s Rapid Growth CERRITOS, Ca. – March 7, 2022 – The Oncology Institute of Hope and Innovation (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced
March 7, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 2, 2022 Date of Report (date of earliest event reported) The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39248 (Com
March 7, 2022	EX-10.2	Form of Option Agreement Exhibit 10.2 THE ONCOLOGY INSTITUTE, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE The Oncology Institute, Inc., a Delaware corporation (the ?Company?) has granted to the participant listed below (?Participant?) the stock option (the ?Option?) described in this Stock Option Grant Notice (the ?Grant Notice?), subject to the terms and conditions of The Oncology Institute, Inc. 2021 Incent
March 7, 2022	EX-10.1	Form of Restricted Stock Unit Agreement Exhibit 10.1 THE ONCOLOGY INSTITUTE, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE The Oncology Institute, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of The Oncology
February 22, 2022	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on February 22, 2022 Registration No.
February 22, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 5 tm224844d1ex-filingfees.htm EX-FILING FEES EX-107 Calculation of Filing Fee Tables S-8 (Form Type) The Oncology Institute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(5) Maximum Aggregate Offering Price Fee Rate
February 14, 2022	SC 13G/A	US68236X1000 / ONCOLOGY INSTITUTE INC/THE / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* THE ONCOLOGY INSTITUTE, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68236X100 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 14, 2022	SC 13G/A	US68236X1000 / ONCOLOGY INSTITUTE INC/THE / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) THE ONCOLOGY INSTITUTE, INC. (formerly DFP Healthcare Acquisitions Corp.) (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68236X100 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this sta
February 14, 2022	424B5	Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5)? ?Registration No. 333-261740? Up to 8,927,543 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 91,009,656 Shares of Common Stock Up to 3,177,543 Warrants? ? This prospectus relates to the issuance by us of up to an aggregate of up to 8,927,543 shares of our common stock, $0.0001 par value per share (?Common Stock?), which consists
February 14, 2022	SC 13G/A	US68236X1000 / ONCOLOGY INSTITUTE INC/THE / CITADEL ADVISORS LLC - ONCOLOGY INSTITUTE, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* The Oncology Institute, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securitie
February 10, 2022	SC 13G/A	US68236X1000 / ONCOLOGY INSTITUTE INC/THE / DAVIDSON KEMPNER PARTNERS - THE ONCOLOGY INSTITUTE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Oncology Institute, Inc. (formerly known as DFP Healthcare Acquisitions Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236X100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this State
February 9, 2022	CORRESP	February 9, 2022 CORRESP 1 filename1.htm February 9, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: The Oncology Institute, Inc. Registration Statement on Form S-1/A Filed February 8, 2022 Registration No. 333-261740 Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and R
February 9, 2022	EX-FILING FEES	EX-Filing Fees EX-FILING FEES 5 tm2133664d4ex-filingfees.htm EX-FILING FEES Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables S-1 (Form Type) The Oncology Institute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities* Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(5) Maximum Aggregate Of
February 9, 2022	S-1/A	(as amended by the Company's amended Registration Statement on form S-1/A filed on February 8, 2022) TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on February 8, 2022 Registration No. 333-261740? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) ? Delaware ? ? 8011 ? ? 84-35
January 4, 2022	CORRESP	January 4, 2022 January 4, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: The Oncology Institute, Inc. Withdrawal of Acceleration Request for Registration Statement on Form S-1 Filed December 17, 2021 File No. 333-261740 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on January 3, 2022, i
January 3, 2022	CORRESP	January 3, 2022 January 3, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
December 17, 2021	EX-21.1	Subsidiaries of the registrant Exhibit 21.1 ? List of Subsidiaries ? Name Country (State) Percent Ownership TOI Acquisition, LLC Delaware 100% TOI Management, LLC Delaware 100% Hope, Health & Healing Center California 100% ?
December 17, 2021	S-1	Power of Attorney Table of Contents As filed with the U.S. Securities and Exchange Commission on December 17, 2021 Registration No. 333- ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) ? Delaware 8011 84-356323 (State or other jurisdiction
December 14, 2021	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 14, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
December 14, 2021	EX-4.5	Description of Securities. EX-4.5 2 toi-20211231xex4d5.htm EXHIBIT 4.5 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, The Oncology Institute, Inc. (formerly known as DFP Healthcare Acquisitions Corp.) has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exc
December 9, 2021	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2021 THE ONCOLOGY INSTITUTE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39248 (Commission File
November 26, 2021	SC 13G	DFPH / DFP Healthcare Acquisitions Corp / Agajanian Richy - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oncology Institute, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 23343Q100 (CUSIP Number) November 12, 2021 (Date of Event Which Requires Filling of This Statement) Check the appropriate box to designate the
November 24, 2021	SC 13G	TOI / Oncology Institute Inc (The) / FOG Ventures Investments, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236X100 (CUSIP Number) November 12, 2021 (Date of Event which Requires filing of this Statement) Check the appropriate box to designate the rule pursuan
November 22, 2021	SC 13D	DFPH / DFP Healthcare Acquisitions Corp / M33 Growth I L.P. - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* The Oncology Institute, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 23343Q100 (CUSIP Number) Gabriel Ling c/o M33 Growth I LP 888 Boylston Street, Suite 500 Boston, MA 02199 (Name, Address and Telephone Nu
November 22, 2021	SC 13D	TOI / Oncology Institute Inc (The) / SARIN RAVI YANG - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* The Oncology Institute, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236X100 (CUSIP Number) Ravi Sarin 10207 Clematis Ct, Los Angeles, CA 90077 (424) 333-0154 (Name, Address and Telephone Number of Perso

TOI / The Oncology Institute, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)